Achieve Life Sciences SEC filings document current reports on operating results, cytisinicline development updates, governance matters, material agreements, and capital-structure disclosures. Recent Form 8-K filings include furnished financial-results releases and business updates tied to the company’s late-stage specialty pharmaceutical focus on cytisinicline for nicotine dependence.
The filing record also covers executive and board changes, compensatory arrangements, consulting and separation agreements, shareholder voting matters, security-structure disclosures, and clinical or regulatory disclosures related to the cytisinicline program. These filings provide formal records of the company’s corporate events, financial-condition updates, and governance actions as a public biotechnology issuer.
Achieve Life Sciences, Inc. Chief Financial Officer Benjamin Halladay was granted two equity awards on October 5, 2026: stock options covering 200,000 common shares, with a $7.01 exercise price and an expiration date of October 5, 2036, and 200,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one common share at settlement. The options vest as to 1/4 of the award on the first anniversary and in substantially equal monthly installments over the following 36 months. The RSUs vest as to 1/4 of the award on each of October 5, 2027, October 5, 2028, October 5, 2029, and October 5, 2030. Both awards are subject to Halladay providing service on each vesting date.
ACHIEVE LIFE SCIENCES, INC. appointed Benjamin Halladay as chief financial officer and principal financial officer effective October 5, 2026; Mark Oki steps down as CFO on the same date. The company said Oki’s departure was not related to a disagreement over its financial statements or disclosures.
Halladay’s employment terms include an initial annual salary of $525,000, a discretionary bonus of up to 40% of his then-current base salary, an option to purchase up to 200,000 shares, and 200,000 restricted stock units. Qualifying severance applies after termination without cause or, in connection with a change in control, resignation for good reason; the change-in-control terms include accelerated vesting of unvested awards.
For ACHIEVE LIFE SCIENCES, INC. (ACHV), director Richard Alistair Stewart reported selling 20,626 shares of Common Stock on August 19, 2026 in an open-market transaction at a weighted average price of $8.493 per share, with individual sale prices ranging from $8.4536 to $8.52. Following the sale, he directly holds 208,249 shares and has additional indirect holdings of 359 shares held by his spouse and 882 shares held by Ricanto Limited, of which he is the principal owner.
ACHIEVE LIFE SCIENCES, INC. (symbol ACHV) received a Rule 144 notice from director Richard Alistair Stewart regarding a proposed sale of 20,626 shares of common stock through broker Charles Schwab Corp. The shares have an indicated aggregate market value of $155,107.52, and common shares outstanding are listed as 102,902,490 as of August 19, 2026. The filing also lists how the securities were acquired, including a 1,950,030-share corporate action in 2017 and open-market purchases of 17,500 shares in 2019 and 10,000 shares in 2024.
Logos Global Management LP and affiliated funds reported passive beneficial ownership of common stock of Achieve Life Sciences, Inc. (ACHV) on a Schedule 13G. Logos Global, its related entities, and control persons Arsani William and Graham Walmsley collectively report beneficial ownership of up to 10,538,440 shares of common stock on a shared-voting and shared-dispositive basis, representing 9.99% of the class, calculated on 102,902,490 shares outstanding as of August 11, 2026.
The reported securities include 6,951,032 shares of common stock, standard options to acquire 1,000,000 shares, and warrants to acquire 2,751,032 shares, with these warrants subject to a 9.99% beneficial ownership limitation. The Global Fund and Opportunities Fund V each hold positions of about 5% of the class, for the benefit of their respective investors. The reporting persons state the holdings were not acquired and are not held for the purpose of changing or influencing control and disclaim beneficial ownership except to the extent of their pecuniary interests.
Achieve Life Sciences, Inc. entered into an Open Market Sale agreement with Jefferies LLC to establish an at-the-market equity offering program. Under this ATM program, the company may, at its sole discretion, sell shares of common stock with an aggregate offering price of up to $150.0 million from time to time through Jefferies as sales agent.
Jefferies will receive up to 3.0% of the aggregate gross proceeds from any sales and will use commercially reasonable efforts to place the shares in transactions deemed to be an “at the market offering” under Rule 415(a)(4). The program can be suspended by the company at any time and will end upon sale of the maximum program amount or termination of the agreement. Net proceeds are currently intended for commercialization of cytisinicline, funding a Phase 3 clinical trial for cytisinicline for e-cigarette cessation, and for working capital and general corporate purposes.
Achieve Life Sciences is establishing an at-the-market equity program to sell up to $150.0 million of common stock through Jefferies LLC under an existing $300.0 million shelf registration. Shares will be sold from time to time on Nasdaq under the symbol ACHV, with Jefferies earning up to 3.0% of gross proceeds as sales agent and being deemed an underwriter.
Based on 102,717,200 shares outstanding as of June 30, 2026 and an assumed sale of 20,689,655 shares at $7.25, shares outstanding would rise to 123,406,855. Net tangible book value would move from $(0.16) to $1.04 per share, implying $6.21 per-share dilution for new investors.
The company, a late-stage clinical specialty pharmaceutical business focused on commercializing cytisinicline for nicotine dependence, intends to use any net proceeds to fund cytisinicline commercialization, a Phase 3 trial for e-cigarette cessation, and for working capital and general corporate purposes.
Achieve Life Sciences, Inc. has a significant shareholder disclosure from Janus Henderson Group Ltd., which, through its affiliated asset managers, may be deemed the beneficial owner of 5,502,064 shares of common stock, including shares obtainable via warrants. This represents 5.4% of the outstanding common stock. The Janus Henderson asset managers hold shared voting and dispositive power over 5,502,064 shares and no sole power. Economic rights, including dividends and sale proceeds, belong to the underlying client accounts termed Managed Portfolios; only Janus Henderson Enterprise Fund Ltd. has rights over more than five percent of the common stock.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline for nicotine dependence. For the three and six months ended June 30, 2026, it reported net losses of $74.8 million and $84.9 million, compared with $12.7 million and $25.5 million in the prior-year periods. The sharp increase was mainly driven by a non-cash $48.5 million loss from the change in fair value of newly issued warrant liabilities and $8.8 million of warrant issuance costs, along with higher general and administrative expenses and stock-based compensation.
Cash, cash equivalents and marketable securities rose to $187.3 million as of June 30, 2026 from $36.4 million at December 31, 2025, primarily reflecting a $168.2 million April 2026 private placement. Despite this, stockholders’ equity turned negative at $(14.7) million, largely due to recognizing a $182.7 million warrant liability. The company has an accumulated deficit of $345.2 million, no product revenue, and remains dependent on external financing, but management believes existing resources are sufficient to meet obligations for at least the next 12 months. Key risks include obtaining FDA approval for cytisinicline, reliance on third-party manufacturing and plant-derived supply, and an ongoing arbitration with Sopharma over supply arrangements.